Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation

Fig. 5

Effect of canagliflozin on vasorelaxation. a End-systolic blood pressure and arterial elastance of vehicle-treated (sham + vehicle, n = 7) and canagliflozin-treated (sham + canagliflozin, n = 7) healthy (sham-operated) rats from the second part of the in vivo study. b Effect of canagliflozin on endothelium-dependent vasorelaxation in healthy aortic rings in vitro (n = 10 aortic rings in each group). c Effect of canagliflozin on endothelium-independent vasorelaxation in healthy aortic rings in vitro (n = 10 aortic rings in each group). Student t-test P values are reported with ticked lines between two groups or as: *P < 0.05. ACh acetylcholine, cana canagliflozin, DMSO dimethyl sulfoxide, pD2 − logEC50, Rmax maximal vasorelaxation, SNP sodium nitroprusside

Back to article page